ALIAXIN SV Injection Solution for

What is ALIAXIN SV

ALIAXIN SV is a sterile, single 1 mL pre-filled syringe containing cross‑linked **hyaluronic acid (HA)**, designed for cosmetic use. As a dermal filler, it restores volume, smooths moderate-to-deep facial lines, and enhances facial contours.

• Formulation: Monophasic HA (~20–25 mg/ml), non-animal origin, cross-linked for durability and biocompatibility :contentReference[oaicite:1]{index=1}.
• Indications: Treats nasolabial folds, marionette lines, oral commissures, chin contouring, and lip augmentation (for patients ≥ 21 years) :contentReference[oaicite:2]{index=2}.
• Benefits: Immediate results, predictable integration, low allergy risk, and reversible with hyaluronidase if needed :contentReference[oaicite:3]{index=3}.
• Limitations: Effects typically last 6–12 months depending on area treated; not permanent :contentReference[oaicite:4]{index=4}.

ALIAXIN SV is a reliable and reversible tool for enhancing facial aesthetics, with a favorable safety profile and immediate efficacy.

How to use ALIAXIN SV

Administration requires a licensed professional using precise techniques and strict aseptic conditions.

• Preparation: Verify packaging integrity and expiry date; cleanse the skin with alcohol-based antiseptic; avoid quaternary ammonium solutions that may affect the filler :contentReference[oaicite:5]{index=5}.
• Needle handling: Typically uses 30G needles for precise placement; assemble securely onto syringe :contentReference[oaicite:6]{index=6}.
• Injection technique: Mid-to-deep dermal injection using linear threading, bolus, or fanning—depending on the area treated (e.g., nasolabial folds vs lips) :contentReference[oaicite:7]{index=7}.
• Volume: Generally 0.5–1 mL per session, tailored to patient anatomy and desired outcome :contentReference[oaicite:8]{index=8}.
• Post-injection: Light massage to distribute the gel, apply a cold compress to reduce swelling; advise avoiding makeup, alcohol, vigorous activity, and sun exposure for 24 hours :contentReference[oaicite:9]{index=9}.
• Follow-up: Schedule a review 2–4 weeks later to assess efficacy and consider minor touch-ups if needed.
• Patient briefing: Inform patients they may experience mild swelling, bruising, tenderness, and that full effects become apparent within a week.

Careful technique and patient education support safe, satisfactory outcomes.

Mode of Action ALIAXIN SV

ALIAXIN SV operates via mechanical volume restoration and biological interactions:

• Volume augmentation: Cross-linked HA gel fills and supports tissue, smoothing wrinkles and enhancing shape :contentReference[oaicite:10]{index=10}.
• Hydration: HA’s ability to bind water—up to a thousand times its weight—plumps and hydrates the skin, improving elastico-turgor :contentReference[oaicite:11]{index=11}.
• Integration: Monophasic formula ensures even integration, reducing the risk of lumps or nodules :contentReference[oaicite:12]{index=12}.
• Stimulation: HA presence may activate fibroblasts and promote collagen synthesis, enhancing skin quality over time :contentReference[oaicite:13]{index=13}.
• Degradation: The gel gradually breaks down via hyaluronidase enzymes and mechanical forces; results fade within 6–12 months depending on the treated area :contentReference[oaicite:14]{index=14}.

This combination of immediate support and longer-term tissue benefits delivers natural and lasting aesthetic improvements.

ALIAXIN SV Interactions ALIAXIN SV

ALIAXIN SV's localized use means systemic drug interactions are minimal, but certain local factors are important:

• Antiseptics: Avoid benzalkonium chloride; use alcohol-based prep to maintain HA integrity :contentReference[oaicite:15]{index=15}.
• Bleeding risk: Patients using NSAIDs, aspirin, or anticoagulants may have increased bruising; consider pausing medication before treatment :contentReference[oaicite:16]{index=16}.
• Other procedures: Avoid performing lasers, chemical peels, or micro-needling on the same area for at least a week post-injection :contentReference[oaicite:17]{index=17}.
• Hyaluronidase: An essential rescue agent; must be available in case of vascular compromise or over-correction :contentReference[oaicite:18]{index=18}.

Clear procedural planning and accurate patient history help minimize risks and improve outcomes.

Dosage of ALIAXIN SV

• Syringe volume: 1 mL HA per syringe at ~20–25 mg/mL concentration.
• Typical dosing:
  • Nasolabial folds/marionette lines: 0.5–1 mL;
  • Lips (augmentation/lip lines): 0.5 mL per lip;
  • Chin/cheek: 0.5–1 mL depending on contouring need.
• Session plan: Usually a single session; possible minor touch-up after 2–4 weeks.
• Maintenance: Typically repeat every 6–12 months based on individual metabolism and lifestyle :contentReference[oaicite:19]{index=19}.
• Technique: Low-pressure microbolus or linear threading ensures precise placement and minimizes complications.
• Safety limit: Avoid overcorrection; follow conservative approach with incremental enhancement.

Dosing should be customized to patient needs, facial anatomy, and desired aesthetic results.

Possible side effects of ALIAXIN SV

• Common (< 7 days): Redness, swelling, hesitation, bruising, pain/tenderness, itching, heat at injection site—usually resolve within a week :contentReference[oaicite:20]{index=20}.
• Moderate (5–10%): Small lumps/nodules or asymmetry; often responsive to massage or minor hyaluronidase treatment :contentReference[oaicite:21]{index=21}.
• Rare (< 1%): Infections, sterile granulomas, hypersensitivity, vascular occlusion leading to necrosis—requires urgent intervention :contentReference[oaicite:22]{index=22}.
• Other: Mild headache or bleeding in intra-articular use (not applicable here).

Most reactions are mild and self-limiting. Prompt recognition and management of serious complications are critical for patient safety.

ALIAXIN SV Contraindications ALIAXIN SV

• Absolute:
  • Known hypersensitivity to HA or syringe components (e.g., lidocaine) :contentReference[oaicite:23]{index=23};
  • Active cutaneous infection/inflammation at treatment site :contentReference[oaicite:24]{index=24};
  • Bleeding disorders or unmodifiable anticoagulation therapy :contentReference[oaicite:25]{index=25}.
• Relative:
  • Pregnancy/breastfeeding—insufficient safety data :contentReference[oaicite:26]{index=26};
  • Autoimmune disease—evaluate based on severity;
  • History of keloids or pigmentation disorders—consider caution :contentReference[oaicite:27]{index=27}.

Thorough screening ensures safe and appropriate patient selection.

Storage of ALIAXIN SV

• Temperature: Store between 2–25 °C (36–77 °F); protect from freezing and excessive heat :contentReference[oaicite:28]{index=28}.
• Packaging: Keep syringe sealed in original blister until use—protect from light and moisture.
• Sterility: Use single-use only; discard unused portions post-injection.
• Expiry: Use before printed date; do not use expired or compromised product.
• Disposal: Dispose of syringe and needle as per medical waste regulations.

Proper storage preserves HA stability, sterility, and guarantees safe administration.